Bionano Genomics, Inc. (BNGO)

Market Cap	20.08M
Revenue (ttm)	33.33M
Net Income (ttm)	-135.78M
Shares Out	95.88M
EPS (ttm)	-1.92
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,929,520
Open	0.230
Previous Close	0.225
Day's Range	0.201 - 0.230
52-Week Range	0.201 - 2.270
Beta	2.37
Analysts	Hold
Price Target	1.00 (+377.56%)
Earnings Date	Nov 13, 2024

About BNGO

Bionano Genomics, Inc. provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearizatio...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Aug 21, 2018
• Employees: 344
• Stock Exchange: NASDAQ
• Ticker Symbol: BNGO
• Website: https://www.bionano.com

Financial Performance

In 2023, Bionano Genomics's revenue was $36.12 million, an increase of 29.90% compared to the previous year's $27.80 million. Losses were -$232.49 million, 75.3% more than in 2022.

Analyst Forecast

According to 3 analysts, the average rating for BNGO stock is "Hold." The 12-month stock price forecast is $1.0, which is an increase of 377.56% from the latest price.

Price Target

$1.0

(377.56% upside)

Analyst Consensus: Hold